• PDF: Delivered by email usually within 48 UK business hours.

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

  • Publication Date:April 2013
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:36

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing RSV Market. The report identifies and analyses the key companies shaping and driving the global RSV market. The report provides insight into the competitive RSV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for RSV
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the RSV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the RSV Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global RSV market landscape? Identify, understand and capitalize
  • Table of Contents
  • 2 Introduction
    • 2.1 Catalyst
  • 3 Market Outlook
    • 3.1 US
      • 3.1.1 Forecast
      • 3.1.2 Key Events
      • 3.1.3 Drivers and Barriers - Global Issues
  • 4 Current and Future Players
    • 4.1 Overview
    • 4.2 Trends in Corporate Strategy
    • 4.3 Company Profiles
      • 4.3.1 AstraZeneca (MedImmune)
      • 4.3.2 Novavax
  • 5 Appendix
    • 5.1 Bibliography
    • 5.2 Abbreviations
    • 5.3 Methodology
    • 5.4 Forecasting Methodology
      • 5.4.1 Number of eligible patients for prophylaxis
      • 5.4.2 Utilization rates of Synagis
      • 5.4.3 Patient share and generic erosion
      • 5.4.4 Weight of high risk infants
      • 5.4.5 Cost per day
      • 5.4.6 Number of prophylaxis days per year
      • 5.4.7 Annual cost of therapy
      • 5.4.8 Patient compliance
      • 5.4.9 Total sales
    • 5.4.10 Drugs Included in Each Therapeutic Class
    • 5.4.11 Launch and Patent Expiry Dates
    • 5.4.12 General Pricing Assumptions
    • 5.4.13 Individual Drug Assumptions
    • 5.5 Physicians and Specialists Included in this Study
    • 5.6 About the Authors
      • 5.6.1 Authors
      • 5.6.2 Epidemiologist
      • 5.6.3 Global Head of Healthcare
    • 5.7 About GlobalData
    • 5.8 Contact Us
    • 5.9 Disclaimer
  • 1.1 List of Tables
    • Table 1: US Sales Forecasts ($m) for Synagis, 2012-2022
    • Table 2: Key Events Impacting Sales for RSV Prophylactics in the US, 2012
    • Table 3: Pediatric RSV Market - Drivers and Barriers, 2012
    • Table 4: Key Companies in the Pediatric RSV Prophylactic Market - United States, 2012
    • Table 5: AstraZeneca's RSV Prophylactics Portfolio Assessment, 2013
    • Table 6: AstraZeneca SWOT Analysis, 2012
    • Table 7: Novavax's Pediatric RSV Prophylactics Portfolio Assessment, 2012
    • Table 8: Novavax SWOT Analysis, 2012
    • Table 9: Key Launch Date
    • Table 10: Key Patent Expiries
  • 1.2 List of Figures
    • Figure 1: Company Portfolio Gap Analysis in Pediatric RSV, 2012-2022
+44 20 8816 8548

Ask a question about PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

Enter the characters you see in the picture below
Captcha